This activity was originally broadcast in conjunction with AMCP 2025.
Program Description
The JAK/STAT pathway plays a major role in the pathogenesis of myelofibrosis. JAK inhibitors improve symptoms of myelofibrosis but may cause cytopenias and have modest effects on bone marrow fibrosis. Patients often develop clinical resistance over time, making switching to another JAK inhibitor therapy a promising treatment option. This session will provide an overview of myelofibrosis, outlining its significant clinical burden and how the use of newer agents in more personalized treatment approaches may address myelofibrosis progression and improve outcomes for patients with relapsed/refractory disease. Key managed care considerations, such as treatment selection, sequencing, and cost-effectiveness will be discussed. The discussion will encompass strategies for oncology and managed care professionals to optimize treatment plans, ensuring patients receive appropriate medications, with a focus on managing treatment-related toxicities, minimizing disease progression, and improving quality of life for patients with myelofibrosis.
Target audience: Managed care pharmacists, oncology pharmacists
Type of activity: Application
Release date: April 9, 2025
Expiration date: April 9, 2026
Time to complete activity: 1.5 hours
Learner level: Intermediate
Educational Objectives
At the completion of this activity, participants will be able to:
- Differentiate between the approved JAK inhibitors based on clinical data and guideline recommendations for use in the treatment of myelofibrosis.
- Explore evidence-based second-line treatment plans for patients with myelofibrosis who have relapsed, are refractory, or have developed intolerance to previous JAK inhibitor therapy.
- Explore managed care strategies that facilitate appropriate treatment and supportive care for patients with myelofibrosis, aimed at improving resource utilization and patient outcomes.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
